<DOC>
	<DOCNO>NCT00533520</DOCNO>
	<brief_summary>Evaluation Dosing Interval Higher Doses Ranibizumab patient wet age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Evaluation Dosing Interval Higher Doses Ranibizumab</brief_title>
	<detailed_description>Phase 4 study test safety , tolerability effectiveness high dos ( 1.0 mg 2.0 mg ) ranibizumab versus standard dose ( 0.5 mg ) , adult age relate macular degeneration never treat ranibizumab . An additional purpose determine high dos ( 1.0 mg 2.0 mg ) ranibizumab increase time dose beyond currently need 0.5 mg dose .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Treatment naive macular degeneration patient choroidal neovascularization &gt; 50 year old Visual acuity 20/40 20/320 Pregnancy Previous history thromboembolic event include myocardial infarction stroke</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>